Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Bruno, Benedetto
First
;
Gay, Francesca;Giaccone, Luisa;D'Agostino, Mattia;Boccadoro, Mario
Last
2021-01-01

Abstract

Chimeric antigen receptor (CAR) T cells (CAR-T) have dramatically changed the treatment landscape of B-cell malignancies, providing a potential cure for relapsed/refractory patients. Long-term responses in patients with acute lymphoblastic leukemia and non Hodgkin lymphomas have encouraged further development in myeloma. In particular, B-cell maturation antigen (BCMA)-targeted CAR-T have established very promising results in heavily pre-treated patients. Moreover, CAR-T targeting other antigens (i.e., SLAMF7 and CD44v6) are currently under investigation. However, none of these current autologous therapies have been approved, and despite high overall response rates across studies, main issues such as long-term outcome, toxicities, treatment resistance, and management of complications limit as yet their widespread use. Here, we critically review the most important pre-clinical and clinical findings, recent advances in CAR-T against myeloma, as well as discoveries in the biology of a still incurable disease, that, all together, will further improve safety and efficacy in relapsed/refractory patients, urgently in need of novel treatment options.
2021
106
8
2054
2065
https://haematologica.org/article/view/haematol.2020.276402
https://doi.org/10.3324/haematol.2020.276402
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327729/
Bruno, Benedetto; Wäsch, Ralph; Engelhardt, Monika; Gay, Francesca; Giaccone, Luisa; D'Agostino, Mattia; Rodríguez-Lobato, Luis-Gerardo; Danhof, Sophi...espandi
File in questo prodotto:
File Dimensione Formato  
[PUBLISHED Vsn.] Bruno et al - 2021 - 10228-Article Text-75061-2-10-20210726.pdf

Accesso aperto

Descrizione: [Published Vsn.] Bruno B et al. Haematologica. 2021 Aug 1;106(8):2054-2065. doi: 10.3324/haematol.2020.276402. PMID: 33792221; PMCID: PMC8327729. Open access. © 2021 Ferrata Storti Foundation. Available at: https://haematologica.org/article/view/haematol.2020.276402 | https://doi.org/10.3324/haematol.2020.276402 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327729/
Tipo di file: PDF EDITORIALE
Dimensione 700.25 kB
Formato Adobe PDF
700.25 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1790957
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact